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Abstract
Background: The recent development of tau-specific positron emission tomography (PET) tracers has allowed in
vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau
pathology along with cognitive impairment. In this study, we investigated the relationships of cerebral tau
deposition ([18F]THK5317-PET) and metabolism ([18F]FDG-PET) with concomitant cognitive function in patients
with probable Alzheimer’s disease (AD).
Methods: Nine patients diagnosed with AD dementia and 11 with prodromal AD (mild cognitive impairment,
amyloid-positive on [11C]PiB-PET) were included in this study. All patients underwent PET scans using each tracer,
as well as episodic memory and global cognition assessment. Linear models were used to investigate the association
of regional [18F]THK5317 retention and [18F]FDG uptake with cognition. The possible mediating effect of local
metabolism on the relationship between tau deposition and cognitive performance was investigated using
mediation analyses.
Results: Significant negative associations were found between [18F]THK5317 regional retention, mainly in temporal
regions, and both episodic memory and global cognition. Significant positive associations were found between [18F]FDG
regional uptake and cognition. The association of [18F]FDG with global cognition was regionally more extensive than that
of [18F]THK5317, while the opposite was observed with episodic memory, suggesting that [18F]THK5317 retention might
be more sensitive than [18F]FDG regional uptake to early cognitive impairment. Finally, [18F]FDG uptake had a mediating
effect on the relationship between [18F]THK5317 retention in temporal regions and global cognition.
Conclusions: These findings suggest a mediating role for local glucose metabolism in the observed association between
in vivo tau deposition and concomitant cognitive impairment in AD.
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Background
Alzheimer’s disease (AD) is characterized by the cerebral
accumulation of amyloid-beta (Aβ) into plaques and
hyperphosphorylated tau into neurofibrillary tangles (NFT),
as well as synaptic and neuronal loss. These different fea-
tures exhibit distinct patterns of progression along the time
course of the disease. Aβ pathological deposition spreads
early throughout the neocortex, precedes by many years
the onset of clinical symptoms [1], and is not – or is only
poorly – associated with markers of atrophy and hypometa-
bolism [2]. The latter two, supposedly more downstream
processes, better relate to clinical symptoms [3, 4] and have
a tight relationship with the stereotypical regional distribu-
tion of NFT pathology [5, 6]. The general thesis is that the
intra-neuronal accumulation of tau disrupts the neuronal
activity, before leading to the destruction of the affected
nerve cells and ultimately to cognitive decline. Autopsy
studies have, indeed, confirmed a relationship between
NFT and cognitive impairment [7, 8]. However, the rela-
tionship between the tau lesions and early cognitive impair-
ment currently remains elusive, as postmortem data are
mostly obtained when severe impairment has occurred [8].
So far, only cerebrospinal fluid (CSF) sampling has
been able to provide insight into in vivo tau changes in
the brains of patients and to relate these changes to con-
comitant symptoms. However, conflicting results have
been reported regarding the relationship between CSF
tau biomarkers and NFT pathology [9–12], limiting the
validity of such biomarkers in reflecting the pathological
progression. Furthermore, CSF biomarkers cannot provide
information about the spatial distribution of lesions.
The recent development of tau-specific positron emission
tomography (PET) tracers now allows in vivo quantification
of the regional distribution of tau deposition (for reviews,
see Dani et al. [13] and Villemagne et al. [14]) and offers
the opportunity to monitor the progression of tau path-
ology along with other markers, including cognitive de-
cline [15]. The tracer [18F]THK5317 (also known as
(S)-[18F]THK5117) has high target specificity and se-
lectivity [16] and favorable pharmacokinetic properties
for non-invasive imaging of tau pathology [17], with good
discrimination of AD patients from healthy controls in
in vivo PET studies [18, 19].
Theoretical models of AD pathophysiology suggest a
sequential association of events in which tau pathology
would precede neuronal dysfunction (as identified by
[18F]FDG PET) that would further affect downstream
cognitive processes [20]. Cerebral metabolic disturbances
may then play the intermediate between tau deposition
and cognitive impairment. In this study, we investigated
the relationship between in vivo regional tau deposition
(using [18F]THK5317 PET) and cognitive performance in
patients with probable AD. In addition, we investigated
the possible mediation role of cerebral metabolism (using
[18F]FDG PET) in this association.
Methods
Participants
All patients included in this study were enrolled in a
larger research study [18], for which they underwent
[18F]THK5317, [18F]FDG, and [11C]PiB PET imaging.
The patients were referred to the Memory Clinic at the
Department of Geriatric Medicine, Karolinska University
Hospital (Stockholm, Sweden), because of memory
complaint. They underwent thorough clinical investiga-
tion including medical history, apolipoprotein E (ApoE)
genotyping, neuropsychological assessment, and structural
magnetic resonance imaging (MRI). Patients diagnosed
with AD dementia fulfilled the revised research criteria for
typical probable AD [21], while patients diagnosed with
mild cognitive impairment (MCI) met the Petersen criteria
[22]. The diagnosis was made by consensus of an expert
committee.
Only patients with an amyloid-positive [11C]PiB PET
scan (see the “PET image pre-processing” section) [23]
were included in this study, as they are the most likely
to be on the AD pathway. This resulted in 11 patients
with amnestic MCI – subsequently referred to as pro-
dromal AD patients [21] – and nine patients diagnosed
with AD dementia.
All patients and their caregivers provided written in-
formed consent prior to research investigations, which
were conducted according to the Declaration of Helsinki
and subsequent revisions. The research project was ap-
proved by the regional Human Ethics Committee in
Stockholm, as well as by the Radiation Safety Committee
of Uppsala University Hospital, Sweden.
Neuropsychological assessment
Global cognitive performance was assessed using two
measures: the mini mental state examination (MMSE)
and the full-scale intelligence quotient (FSIQ), which is
based on five subtests from the revised Weschler adult
intelligence scale (Similarities, Information, Block Design,
Digit Span, and Digit Symbol).
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Episodic memory performance was assessed using three
tests: learning and delayed recall from the Rey auditory
verbal learning (RAVL) test, and delayed recall from the
Rey-Osterrieth complex figure (Rey) test. In summary, five
scores were considered: MMSE and FSIQ (global cogni-
tion), RAVL learning, RAVL delayed recall, and Rey de-
layed recall (episodic memory).
Image acquisition
All patients underwent a three-dimensional T1-weighted
(3D T1W) MRI sequence, 60-min [18F]THK5317 and
[11C]PiB dynamic PET scans to image tau and fibrillar Aβ
depositions, respectively, and a 15-min [18F]FDG static PET
scan to image glucose metabolism. The [18F]THK5317 and
[11C]PiB PET scans were acquired on an ECAT EXACT
HR+ scanner (Siemens/CTI) or a Discovery ST PET/CT
scanner (GE) at the Uppsala PET Centre (Uppsala,
Sweden), after intravenous injection of 212 ± 42 MBq and
253 ± 69 MBq of the tracers, respectively. The [18F]FDG
PET scans were acquired on a Biograph mCT PET/CT
scanner (Siemens) at the Department of Nuclear Medicine,
Karolinska University Hospital Huddinge (Stockholm,
Sweden), with a 15-min static run, 30 min after injection of
3 MBq/kg. All acquisitions were reconstructed using or-
dered subset expectation maximization.
Regions of interest
Fifty bilateral regions of interest (ROIs), excluding the
subcortical nuclei, were obtained from the pre-existing
Harvard-Oxford structural atlas (FSL software, The Uni-
versity of Oxford) for regional quantification analyses.
For each participant, the T1W MRI image was segmented
into gray and white matter tissue maps using SPM8 soft-
ware and the inverse non-linear transformation resulting
from this segmentation was used to warp the atlas into
each individual’s native T1W space. An inclusive binary
gray matter mask was subsequently applied to the result-
ing atlas to obtain individual gray matter atlases.
PET image pre-processing
Individual dynamic [18F]THK5317 PET images were co-
registered onto the individual T1W images with PMOD
v.3.5 software (PMOD Technologies Ltd., Adliswil,
Switzerland). In order to minimize a possible spill-over
effect on the signal from white matter, MRI-based partial
volume correction based on individual T1 was applied
to the dynamic [18F]THK5317 PET images, using the
Muller-Gartner method [24] as implemented in PMOD
v.3.5 software. The reference Logan graphical method
was then applied to the corrected images over the 30 to
60-min scan interval, with cerebellar gray matter as a ref-
erence [17], in order to create distribution volume ratio
(DVR) images for each participant.
Summed [11C]PiB PET (40–60 min) and [18F]FDG PET
(30–45 min) images from patients were co-registered onto
their individual T1W MRI images using SPM8 and stan-
dardized uptake value ratio (SUVR) images were created
with reference to the cerebellar gray matter for [11C]PiB
and the pons for [18F]FDG. An SUVR threshold of
1.41 for amyloid positivity was applied to [11C]PiB PET
data [23].
Statistical analysis
Group differences between patients with prodromal AD
(i.e. MCI, PiB-positive) and patients with AD dementia
were assessed using the Chi-square test for discrete vari-
ables and the Mann–Whitney test for continuous variables.
Linear regression models were performed to investi-
gate the association of [18F]THK5317, [18F]FDG, and
[11C]PIB regional retention with cognitive performance
in patients with AD (both prodromal AD and AD de-
mentia). These models were performed using the Linear
Model (LM) R package. Graphical representations of
significant linear associations were obtained with the
ggplot2 package v.1.0.1, as implemented in R.
All statistical analyses were performed using the R
v.3.1.0 software (The R Foundation for Statistical Com-
puting, http://www.r-project.org/). The significance level
for all statistical tests and models was set at p < 0.05.
Association of [18F]THK5317 and [18F]FDG regional retention
with cognitive performance in probable Alzheimer’s disease
The first linear regression model determined the associ-
ation between cognitive performance and [18F]THK5317
retention after adjusting only for the delay between assess-
ment times. Because age may have an effect on cognition
and tau deposition [25, 26], a second model was used to
determine the association between cognitive performance
and [18F]THK5317 retention with adjustment for both
delay and age. The p value, t-value and the standardized β
coefficient (further referred to as “β”) associated with the
PET tracers’ regional retention were obtained for each
model, as well as the Akaike information criterion (AIC).
The AIC is a measure of the relative quality of statistical
models, allowing determining among several statistical
models which model is “best.” The different linear models
were compared using ANOVA. The false discovery rate
(FDR) correction for multiple comparisons was applied,
with both corrected and uncorrected results reported.
The same linear regression models and same correc-
tions were used to investigate the association of both
[18F]FDG uptake and [11C]PIB retention with cognitive
performance in our sample.
In summary, the following linear models were tested:
Model 1: Cognition = PET tracers’ regional retention +
delay + intercept;
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Model 2: Cognition = PET tracers’ regional retention +
delay + age + intercept.
Mediation analyses
The possible mediating effect of local (i.e. in the same
ROI) hypometabolism on the relationship between tau
deposition and cognitive performance was investigated
using exploratory analyses. In its simpler form, a medi-
ation analysis explores the hypothesis that the relationship
between an independent variable X and a dependent vari-
able Y is mediated by a third variable M. This hypothesis
explores causal relationships and assumes that the inde-
pendent variable would have an indirect effect on the
dependent variable through the mediator, i.e. X affects M,
which in turn affects Y. Mediation analyses were per-
formed using regional [18F]THK5317 retention (adjusted
for age and delay) as the independent variable, regional
[18F]FDG uptake (adjusted for age and delay) as the medi-
ator, and cognitive performance as the dependent variable,
when the following conditions were met in the first linear
model: (1) cognitive performance was significantly associ-
ated with [18F]FDG regional uptake (without correcting
for multiple comparisons); and (2) [18F]FDG uptake was
also associated – as measured by linear regression – with
[18F]THK5317 retention in the same region. The average
causal mediation effect (ACME) and the average direct ef-
fect (ADE) were obtained, using the mediation R package,
and assessed for significance based on non-parametric
bootstrapping (5000 simulations, p < 0.05) for all medi-
ation analyses.
Results
The demographics and cognitive performance results for
the patient groups are described in Table 1. The median
[interquartile range] delay period in days between cog-
nitive assessment and [18F]THK5317, [18F]FDG, and
[11C]PiB PET scans was 71.5 [73.5], 59.5 [163.5], and
70.5 [79.8], respectively.
Association between [18F]THK5317 regional retention and
cognitive performance in probable AD
In the first linear model, adjusting for delay between as-
sessments, significant negative associations were found
between [18F]THK5317 regional retention and global
cognition as measured by FSIQ performance. The cortical
regions involved in this association were mainly temporal,
including the posterior part of the parahippocampal gyrus,
the fusiform gyrus, and the inferior, middle, and superior
temporal gyri (Fig. 1), with occipital regions and the
middle frontal gyrus, the posterior cingulate gyrus, the
parietal operculum, and the precuneus also involved.
[18F]THK5317 retention in the posterior parahippocampal
gyrus and the inferior temporal gyrus (posterior part) was
also negatively associated with the MMSE score. Significant
negative associations were found between [18F]THK5317
regional retention and episodic memory performance, as
assessed by the RAVL learning and Rey delayed recall tests.
These associations mainly concerned temporo-parieto-
occipital regions (Fig. 2a and Additional file 1).
After correcting for multiple comparisons, the nega-
tive association between [18F]THK5317 retention in the
inferior temporal gyrus and the FSIQ score remained
significant (see Additional file 1).
Association between [18F]FDG regional uptake and
cognitive performance in probable AD
Significant positive associations were found between
[18F]FDG regional uptake and global cognition – using
both FSIQ and MMSE scores, after adjusting for delay.
These associations were found in a large number of cortical
regions that were widespread throughout the cortex. Sev-
eral associations survived correction for multiple compari-
sons (Fig. 2b and Additional file 1). A few significant
positive associations were found between [18F]FDG regional
uptake and episodic memory performance, as measured by
Table 1 Summary of group demographics and






Age at testing (years) 69.7 ± 6.7 67.3 ± 7.1
Education 12.5 ± 3.3 13.3 ± 2.7
Gender (M/F) 5/6 2/7
ApoE ε3ε3/ε3ε4/ε4ε4 4/1/5 1/5/3
Cognitive functions
Global cognition
MMSE 27.7 ± 3.0 22.6 ± 3.3**
FSIQ 92.6 ± 12.2 69.2 ± 21.6*
(z-scores) −0.8 ± 0.9 −2.6 ± 1.6
Episodic memory
RAVL, learning 34.7 ± 10.0 20.9 ± 5.7**
(z-scores) −1.2 ± 1.0 −2.5 ± 0.5
RAVL, delayed recall 3.8 ± 3.0 1.7 ± 2.2
(z-scores) −1.8 ± 0.9 −2.4 ± 0.6
Rey, delayed recall 12.8 ± 8.1 1.2 ± 1.9**
(z-scores) −1.0 ± 1.2 −2.7 ± 0.3
Performance is expressed as mean ± standard deviation to the mean. Z-scores
were calculated in comparison to a normative population
Statistically significant differences between groups are displayed as
*p < 0.05; **p < 0.01
AD Alzheimer’s disease, ApoE apolipoprotein E, F female, FSIQ full-scale
intelligence quotient, M male, MCI mild cognitive impairment, MMSE mini mental
state examination, PiB Pittsburgh Compound B, RAVL Rey auditory verbal learning
test, Rey Rey-Osterrieth complex figure test
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the RAVL subtests, but they did not survive multiple com-
parisons correction.
Association between [11C]PiB regional retention and
cognitive performance in probable AD
The association between [11C]PiB regional retention and
cognitive performance was also assessed adjusting for
delay between assessments. No significant association
was found, either with or without correction for multiple
comparisons, between cognition and [11C]PiB retention
in any region of interest.
Effect of age
Adding age as a covariate significantly improved the linear
models for a few associations between [18F]THK5317
regional retention and cognition, but not for associations
Fig. 1 Significant associations between regional [18F]THK5317 retention (DVR) and cognition in AD patients, after adjusting for delay. Prodromal
AD patients are displayed in red and AD dementia patients in blue. The graphs also show the p and t values and the standardized β coefficient
associated with regional [18F]THK5317 retention in each model. FSIQ full-scale intelligence quotient, MCI mild cognitive impairment, MMSE mini
mental state examination, RAVL Rey auditory verbal learning test
Fig. 2 Cortical regions of interest where PET tracer retention was significantly associated with cognition in AD patients, after adjusting for delay
(not corrected for multiple comparisons). Linear models assessed the association between cognitive performance using five different tests (each
row) and (a). [18F]THK5317 retention (DVR) or (b). [18F]FDG uptake (SUVR). Regions are defined according to the Harvard-Oxford atlas. T-values for
significant negative associations are displayed with a blue color scale and T-values for significant positive associations are displayed with a red color scale.
FSIQ full-scale intelligence quotient, MMSE mini mental state examination, RAVL Rey auditory verbal learning test, Rey Rey-Osterrieth complex figure test
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between [18F]FDG uptake and cognition (Table 2). The
overall patterns of association with cognitive performance
did not change for either [18F]THK5317 or [18F]FDG (see
Additional file 2).
Mediation analyses
Linear regression analysis found significant negative as-
sociations between [18F]FDG uptake and [18F]THK5317
retention in the posterior inferior temporal gyrus (t =
−2.741; p = 0.013), the posterior middle temporal gyrus
(t = −2.253; p = 0.037), and the occipital fusiform gyrus
(t = −2.176; p = 0.043).
In order to investigate the possible mediating effect for
hypometabolism in these three regions in the relation-
ship between local [18F]THK5317 regional retention and
cognition, mediation analyses were performed using re-
gional [18F]FDG uptake as mediator. Mediation analyses
were applicable for four associations between cognition
and PET regional uptake (Fig. 3). The mediating effect
(ACME) of [18F]FDG was significant in both the poster-
ior inferior temporal and the posterior middle temporal
gyri, while no mediating effect was found in the occipital
fusiform gyrus, for the association with FSIQ. No mediating
effect was found in the posterior inferior temporal gyrus,
for the association with RAVL learning score.
Discussion
[18F]THK5317 regional retention is associated with
cognition
Quantitative assessment of in vivo tau deposition, as
measured by [18F]THK5317 retention, in the brains of
AD patients at different stages of AD revealed a signifi-
cant association with cognition. To our knowledge, this
is the first study investigating the relationship between
regional [18F]THK5317 retention and concomitant cog-
nition in vivo. [18F]THK5317 retention was negatively
associated with both global cognition and episodic mem-
ory. The cortical regions involved in this association
were in agreement with those primarily affected by tau
pathology in AD [27, 28]. These findings support the
hypothesis that regional tau deposition in AD is closely
related to cognitive impairment [8].
A few negative associations between [18F]THK5317 re-
tention and cognition were also found in the parietal
and frontal cortices. While the medial temporal lobe is
among the first to be affected by NFT, the neocortex is
thought to be affected by NFT and neuropil threads at
later stages [27]. The presence of tau lesions in neocor-
tical regions can, however, be observed in some neuronal
layers from Braak stage III [29]. In the light of the re-
ported regional distribution of [18F]THK5317 retention
in AD patients in comparison to controls [18] and previ-
ous in vitro work showing the good binding affinity of
the tracer to tau deposits [16], we hypothesize that our
findings illustrate the presence of tau pathology in neo-
cortical regions that is related to cognitive impairment.
Interestingly, while the association between [18F]THK5317
retention and the FSIQ score was seen in several ROIs,
the association with the MMSE score was only seen in the
inferior temporal gyrus – a finding recently reported with
another tau tracer [30] – and the parahippocampal gyrus.
These results suggest that global cognitive impairment as
measured by composite cognitive scores, such as FSIQ,
would better reflect pathological tau progression from the
early clinical stages than MMSE.
Distinctive pattern of association between cognition and
[18F]FDG regional uptake
Cerebral metabolism, as measured by [18F]FDG uptake,
was positively associated with both global cognition and
episodic memory. The pattern of association with global
cognition was much broader than that observed with
[18F]THK5317, involving frontal, temporal, and parietal
regions. This is consistent with previous studies that
showed metabolic disturbances beyond the temporo-
parietal regions correlating with non-memory per-
formance [31, 32] and suggests that [18F]FDG uptake
may be more selective than [18F]THK5317 retention
with respect to global cognitive impairment. [18F]FDG
uptake was positively associated with episodic memory
in restricted areas of the medial temporal and parietal
Table 2 Akaike information criterion indices for significant linear regression models
FSIQ MMSE RAVL, learning RAVL, delayed recall Rey, delayed recall
Regional retention Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
[18F]THK5317
Amygdala 184 183 119 119 151 149 101 93* 142 138*
Parahippocampal gyrus (post.) 173 170* 114 114 152 154 103 103 138 134*
Parahippocampal gyrus (ant.) 181 178* 116 115 147 145 102 98* 140 133*
Angular gyrus 178 177 118 120 153 155 105 105 137 133*
Model 1: Cognition = [18F]THK5317 regional retention + delay + intercept; Model 2: Cognition = [18F]THK5317 regional retention + delay + age + intercept. Only
associations with significant differences (*) between models (using ANOVA) are displayed
Ant anterior part, FSIQ full-scale intelligence quotient, MMSE mini mental state examination, post posterior part, RAVL Rey auditory verbal learning test,
Rey Rey-Osterrieth complex figure test
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cortices [33], a regional pattern of association less
broad than that seen with [18F]THK5317. This is consist-
ent with the classical association pattern of hypometabo-
lism with memory impairment in AD [4, 34]. The limited
extent of this association, in comparison with that of
[18F]THK5317, suggests that [18F]THK5317 retention
might be more selective than [18F]FDG uptake with re-
spect to early cognitive (i.e. episodic memory) impairment.
Of note, no significant association between regional
[11C]PiB retention and cognition was found in our sample.
Although we acknowledge that [11C]PiB PET retention be-
ing part of the inclusion criteria is a clear source of bias in
its interpretation, this finding highlights the differential re-
lationships of amyloid and tau deposits with symptoms in
the same population of patients with probable AD.
[18F]FDG regional uptake mediates the relationship
between [18F]THK5317 temporal retention and global
cognition
Hypothetical models of biomarker progression in AD
suggest that the increase in cerebral tau pathology would
precede metabolic disturbances, which in turn would
precede the onset of symptoms [35]. The relationships
among these three have, however, remained elusive.
When we investigated the relationship between both
tracers and cognition in these patients, we found evi-
dence of a mediating role for local cerebral glucose me-
tabolism in the relationship between tau deposition and
global cognition – as measured by the FSIQ score. This
mediating effect was observed in two temporal regions:
the inferior and middle temporal gyri. This illustrates
the existence of potential intermediate factors between
pathological lesions in neurons and clinical symptoms
and suggests a regional causal sequence where local ac-
cumulation of tau lesions triggers neuronal dysfunction,
which in turn leads to cognitive impairment. This inter-
mediate role for glucose metabolism between lesions
and symptoms has also been suggested in a recent study
exploring the mediating effect of metabolism in the rela-
tionship between CSF biomarkers and cognition [36].
The authors suggested that the tau-related burden pre-
cedes neurometabolic dysfunction, which results in subse-
quent cognitive impairment. Although the role of tau
deposits, and especially of NFT, in AD is not well under-
stood, their presence intra-cellularly is likely to contribute
to synaptic dysfunction [37] or neuronal activity changes
[38]. These can be indirectly measured in vivo by assessing
regional glucose metabolism. Our findings suggest that
Fig. 3 Causal mediation analyses. The model, presented in (a), assessed the effect of [18F]FDG regional uptake (mediator) on the relationship
between [18F]THK5317 retention (independent variable) in the same region and cognitive performance (dependent variable). (b) Results for the
four associations tested. Significant results are displayed in bold. ACME average causal mediation effect, ADE average direct effect, FSIQ full-scale
intelligence quotient, PET positron emission tomography, RAVL Rey auditory verbal learning test
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tau pathology in temporal regions would interfere with
local neuronal activity, which would further disrupt
neuronal circuitry and lead to cognitive impairment.
We hypothesize that the accumulation of tau would
first trigger minor neuronal disturbance leading to early
(episodic memory) cognitive impairment and then larger
disruption of neuronal functions as reflected by cerebral
glucose hypometabolism leading to more global cognitive
impairment.
Other factors likely to contribute to the association
between tau and cognition
Normal aging has already been found to play a significant
role in cognition [26] as well as in tau deposition [25] and
cerebral glucose metabolism [39] in specific cerebral re-
gions. As a consequence, we adjusted all variables relevant
to age in our linear models, which improved the results
for several associations. Several other factors that could
not be accounted for here, such as neuroinflammation
and genetic factors, may also play a key role in the re-
lationship between tau deposition and cognition [40].
A large body of studies suggest that tau pathology is
necessary but not sufficient to trigger neuronal dysfunc-
tion. Tau itself is seen by some as a key mediator of
amyloid-induced toxicity for neuronal activity (see the re-
view by Liao et al. [41]). We acknowledge that our study
only reflects one aspect of the pathological processes. Fur-
thermore, it is likely that tau lesions in one region could
trigger metabolic dysfunction in remote regions, leading
to further cognitive impairment. The limited sample size
also restricted our investigations to linear models, while
non-linear models might better reflect the relationships
between the variables over time. This deserves to be
addressed in further studies with larger sample sizes. In
addition, because of the large number of regions included
in the analyses, only a few linear models showing a signifi-
cant association between regional PET uptake and cogni-
tion survived after correction for multiple comparisons.
To minimize the number of comparisons, only bilateral
ROIs were investigated. However, hemispheric differences
could be expected, in view of the known specialization of
each hemisphere for memory subtypes.
Conclusions
Our study indicates that the cerebral distribution of tau
deposits assessed in vivo using the [18F]THK5317 PET
tau tracer is strongly associated with cognitive impair-
ment in patients with probable AD. The second major
finding is that tau PET imaging could be more selective
for early cognitive (i.e. episodic memory) impairment
than metabolic changes. Finally, evidence from this study
suggests that metabolic dysfunction could, at least partly,
play a mediating role in the association between tau
pathology and cognitive impairment in AD patients.
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Additional file 1: Association of [18F]THK5317 distribution volume ratio
(DVR) and [18F]FDG standardized uptake value ratio (SUVR) regional
retention with cognitive performance, as determined by linear regression
modeling, after adjusting for delay between assessments. Only significant
p values (<0.05) are displayed. Values in bold indicate associations that
survived false discovery rate (FDR) correction for multiple comparisons.
β standardized β coefficient, FSIQ full-scale intelligence quotient, MMSE
mini mental state examination, RAVL Rey auditory verbal learning test,
Rey Rey-Osterrieth complex figure test. (DOC 186 kb)
Additional file 2: Cortical regions of interest where PET tracer retention
was significantly associated with cognition in AD patients, after adjusting
for delay and age (not corrected for multiple comparisons). Linear
models assessed the association between cognitive performance using
five different tests (each row) and (A). [18F]THK5317 retention (DVR) or (B).
[18F]FDG uptake (SUVR). Regions are defined according to the Harvard-
Oxford atlas. T-values for significant negative associations are displayed
with a blue color scale, and T-values for significant positive associations
are displayed with a red color scale. FSIQ full-scale intelligence quotient,
MMSE mini mental state examination, RAVL Rey auditory verbal learning
test, Rey Rey-Osterrieth complex figure test. (DOC 495 kb)
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